Literature DB >> 18554201

Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease.

Michael O Sweeney1, Anne S Hellkamp, Kenneth A Ellenbogen, Gervasio A Lamas.   

Abstract

UNLABELLED: Sudden Cardiac Death in Elderly Pacemaker Patients.
BACKGROUND: The purpose of this study was to describe the incidence and predictors of sudden cardiac death (SCD) and heart failure (HF) death, and coexisting indications for ICDs and CRT, in patients with sinus node disease (SND) treated with pacemakers. METHODS AND
RESULTS: Baseline variables were used to predict SCD and HF death among 1,135 patients in the Mode Selection Trial, a 6-year trial of pacing mode in SND. There were 73 deaths among 177 patients with EF <or= 35% (41.2%), 46/156 (29.5%) with EF 36-49%, and 147/802(18.3%) with EF >or= 50%. SCD accounted for 21.9%, 23.9%, and 14.3% of deaths with EF <or= 35%, 36-49%, and >or= 50%. HF deaths accounted for 23.3%, 19.6%, and 3.4% of deaths with EF <or= 35%, 36-49%, and >or= 50%. EF <or= 35% predicted SCD (hazard ratio [HR] 3.68, 95% confidence interval [CI] 1.72-7.89, P = 0.002) and HF death (HR 10.17, 95% CI 3.35, 30.82, P = 0.001). Four-year SCD rate with EF <or= 35% was 15.5% (3.9% annually). Nearly one-fifth of patients qualified for ICDs (EF <or= 35%) and half of these had QRS >or= 120 ms. However, >40% died within 33 months (4-year noncardiac death rate approximately 22%).
CONCLUSIONS: Reduced EF predicts SCD and HF death in SND treated with pacemakers. SCD rates among patients with EF <or= 35% are similar to control arms of primary prevention ICD trials, but mortality rates are significantly higher. Whether ICDs or CRT to provide bradycardia support would prolong life in elderly patients with EF <or= 35% and SND merits prospective investigation.

Entities:  

Mesh:

Year:  2008        PMID: 18554201     DOI: 10.1111/j.1540-8167.2008.01209.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  Symptom improvement after upgrade from right ventricular apical to biventricular pacing: Role of right and left ventricular volumes assessed with single-photon emission computed tomographic equilibrium radionuclide angiocardiography.

Authors:  Ian P Clements; Stuart Christenson; David O Hodge; Brian P Mullan; Margaret M Redfield; David L Hayes
Journal:  J Nucl Cardiol       Date:  2010-12-03       Impact factor: 5.952

2.  Dynamic and site-specific impact of ventricular pacing on left ventricular ejection fraction.

Authors:  David Schwartzman; Lauren Johnson; Hidekazu Tanaka; Takeyoshi Ota; John Gorcsan; Bouchra Lamia; Michael R Pinsky; Sanjeev G Shroff
Journal:  Heart Rhythm       Date:  2010-03-03       Impact factor: 6.343

Review 3.  Targeting device therapy: genomics of sudden death.

Authors:  J Michael Frangiskakis; Barry London
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

4.  Which Patients with AV Block Should Receive CRT Pacing?

Authors:  Tanyanan Tanawuttiwat; Alan Cheng
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-03

5.  Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial.

Authors:  Maria F Paton; John Gierula; Haqeel A Jamil; Judith E Lowry; Rowena Byrom; Richard G Gillott; Hemant Chumun; Richard M Cubbon; David A Cairns; Deborah D Stocken; Mark T Kearney; Klaus K Witte
Journal:  BMJ Open       Date:  2019-07-17       Impact factor: 2.692

6.  Predictors of pacemaker dependency in patients implanted with a pacemaker after Transaortic valve replacement.

Authors:  Pablo M Ruiz-Hernandez; Esteban Gonzalez-Torrecilla; Enrique Gutierrez-Ibañez; Hugo Gonzalez-Saldivar; Vanesa Bruña; Gerard Loughlin; Evaristo Castellanos; Pablo Avila; Felipe Atienza; Tomas Datino; Jaime Elizaga; Angel Arenal; Francisco Fernández-Aviles
Journal:  Int J Cardiol Heart Vasc       Date:  2020-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.